Mela Sciences' FDA struggle unveiled; Nanotubes for brain blood vessel imaging;

@FierceMedDev: ICYMI yesterday: Imaging pen may detect skin cancer faster. Article | Follow @FierceMedDev

@StacyALawrence: Med tech M&A gets much, much bigger during the first half. Special report | Follow @StacyALawrence

@VarunSaxena2: ICYMI last week: UPDATED with information from interview of CEO: NeuroPace RNS Stimulator secures add-on payments from CMS. Story | Follow @VarunSaxena2

@EmilyWFierce: Scientists created a 3-D, doughnut-shaped model of the human brain that can imitate neurological function. More from the NYT | Follow @EmilyWFierce

> Dr. Joseph Gulfo, former CEO of Mela Sciences, talks about the battle to get FDA approval for MelaFind in his new book. Review

> Researchers are exploring the use of fluorescence-based brain imaging without requiring craniotomy as an alternative to current, less efficient imaging methods. Study

> Population health and work flow technology company Acupera completed a $4 million financing led by Lightspeed Venture Partners. The funding will be used to scale the company's product development team. Release

Biotech News

@FierceBiotech: ICYMI yesterday: J&J's diabetes combo wins FDA nod in a fast-crowding space. Article | Follow @FierceBiotech

@DamianFierce: Digging into the FDA's priority review voucher. Who's willing to pay big for one? Report | Follow @DamianFierce

@EmilyMFierce: Gene editing method kills cervical cancer cells. More from FierceBiotech Research | Follow @EmilyMFierce

> Tokai pitches a $75M IPO to fund its three-in-one cancer drug. News

> Intercept leaps again as deeper NASH data quiet some fears. Story

> UniQure bets on a gene therapy for heart failure. Article

Pharma News

@FiercePharma: Tops on FP Monday: Former top Sanofi exec Whitaker nabbed by Synta to shuttle cancer drug to market. Article | Follow @FiercePharma

@EricPFierce: Boehringer Ingelheim cutting jobs in Germany in 15% cost reduction move. Article|  Follow @EricPFierce

@CarlyHFierce: Generic Viagra Delivers Hidden Billionaire Duo in Brazil. Bloomberg story | Follow @CarlyHFierce

> Valeant's No. 3 shareholder: We don't need Allergan. Story

> Syria broadens corruption accusations against GlaxoSmithKline. Report

Biotech Research News

> 3-D bioengineered brain tissue grown in lab. Report

> Small molecule inhibitor reverses cognitive deficits of Alzheimer's in mice. More

> Glaxo: Ebola vaccine could be ready by 2015. Item

> Malaria vaccine alternative shows high protection in mice. Article

> Gene editing method kills cervical cancer cells. Story

Pharma Manufacturing News

> Baxter to add recombinant protein processing suite at Singapore plant. More

> Recalls overseen by FDA soar in 2013, 2014. Item

> Report: Immigrants make up 26% of U.S. drug production and distribution workforce. Story

> Pakistan indicts 76 customs officers in fake drug probe. News

> U.S. health emergency facilities ready to produce Ebola drugs. Article

Suggested Articles

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.